Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have ...

Hims & Hers Health, Inc. HIMS has emerged as a transformative player in the personalized healthcare market, showcasing robust ...

BofA Securities has recently reduced Hims & Hers Health Inc (HIMS) stock to Underperform rating, as announced on November 14, 2024, according to Finviz. Earlier, on August 22, 2024, Needham had ...

Lexaria Bioscience (LEXX) announced the engagement of a contract research organization to design and execute a human pilot study evaluating DehydraTECH-liraglutide against Saxenda injectable ...

As a result of the stronger than expected performance of DehydraTECH-processed liraglutide, the Company has made the decision to investigate further with human study GLP-1-H25-5 expected to be ...

As reported on November 20th in Lexaria’s 12-week rodent study with unlimited food available, DehydraTECH-processed liraglutide – administered orally - demonstrated a 5.88% weight ...

As a result of the stronger than expected performance of DehydraTECH-processed liraglutide, the Company has made the decision to investigate further with human study GLP-1-H25-5 expected to be ...

This presents a golden opportunity to tap into Hims & Hers Health, Inc. (HIMS), GoodRx Holdings, Inc. (GDRX), and Talkspace, Inc. (TALK), which are well-positioned to ride the exciting growth wave of ...

Hims & Hers Health, Inc. (NYSE:HIMS) Chief Operating Officer, Melissa Baird, has recently sold a significant amount of company stock, according to a new SEC filing. Over a... Michael Chi, the Chief ...